 Growing evidence suggests that DNA damaging agents, such as duocarmycins, are more efficacious in tumor cell killing than tubulin binders, particularly in case of solid tumors.They have shown activity in a variety of multi-drug resistant (MDR) models.Agents that are part of this class of duocarmycins have the potency in the low picomolar range.